Sickle Cell Disease Market Insight, Epidemiology And Market Forecast - 2034The sickle cell disease treatment market is experiencing signific ...

Pharma/biotech giants Pfizer PFE and Bristol Myers BMY boast of a dominant position in the lucrative oncology space. Oncology or cancer is one of the most sought-after areas in the pharma/biotech ...

NEEDHAM, Mass., June 20, 2025 /PRNewswire/ -- Perceptive Discovery, a global leader in molecular and functional imaging research, today announced the launch of the FIBRE (Fibrosis Imaging ...

Pfizer (NYSE:PFE) stock is a biopharmaceutical firm that had a magnificent breakout in 2021 as the worst of the pandemic sent COVID vaccine demand through the roof. Since that peak, it’s been a ...

Democrats press Pfizer, J&J and others over low tax bills and lobbying as Senate debates Trump's plan By Annika Kim Constantino, CNBC • Published June 17, 2025 • Updated on June 17, 2025 at 1: ...

The lawmakers accuse Pfizer, Merck, J&J, AbbVie and Amgen of paying little to nothing in federal taxes despite generating billions of dollars annually.

Regardless of which you choose, Pfizer's (NYSE: PFE) share price has declined during the period. Pfizer's dismal stock performance in recent years underscores the challenges the big drugmaker faces.